Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhatabi, Hind A., Zohny, Samir F., Shait Mohammed, Mohammed Razeeth, Choudhry, Hani, Rehan, Mohd, Ahmad, Aamir, Ahmed, Farid, Khan, Mohammad Imran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944541/
https://www.ncbi.nlm.nih.gov/pubmed/35326111
http://dx.doi.org/10.3390/antiox11030461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944541/
https://www.ncbi.nlm.nih.gov/pubmed/35326111
http://dx.doi.org/10.3390/antiox11030461

Ejemplares similares